Log In
Print
BCIQ
Print
Print this Print this
 

rociletinib (AVL-301) (formerly CO-1686)

  Manage Alerts
Collapse Summary General Information
Company Celgene Corp.
DescriptionSmall molecule that inhibits the T790M EGFR mutation and the initial activating EGFR mutations
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II/III
Standard IndicationNon-small cell lung cancer (NSCLC)
Indication DetailsTreat non-small cell lung cancer (NSCLC); Treat non-small cell lung cancer (NSCLC) in patients with the T790M EGFR resistance mutation
Regulatory Designation

U.S. - Breakthrough Therapy (Treat non-small cell lung cancer (NSCLC) in patients with the T790M EGFR resistance mutation)

Partner

Clovis Oncology Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today